Illumina, Inc. (NASDAQ:ILMN) showed strong performance with a 23.4% rally after exceeding earnings guidance. CEO Jacob Thaysen highlighted revenue growth in the clinical segment. The company revised its revenue decline projection for fiscal year 2025 to 0.